66 results about "Addiction" patented technology

This invention relates to the field of pharmaceutical technology, and discovers that the natural products boldinine and norboldinine can be used as NTSR1 (Neurotensin receptor-1, NTSR1) receptor antagonists and their applications. The compounds are boldinine and norboldinine ((+)-Laurolitsine), which have NTSR1 receptor antagonistic activity and are NTSR1 receptor antagonists that can prevent and treat alcohol poisoning, addiction, schizophrenia, autism spectrum disorder, and mood disorders. Accordingly, this invention can provide novel NTSR1 receptor antagonist prospective compounds with clear targets for the above-mentioned related diseases.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

The present application relates to cost-effective, practical and scalable synthetic routes for the syntheses for psilocybin (Formula I) and its major metabolite psilocybin (Formula II) and their pharmaceutically acceptable salts. These compounds are useful for the treatment or prevention of mental health disorders, such as major depressive disorder, anxiety and addiction disorders, among others CNS disorders.

The present invention relates to a compound, of the formula:Wherein variables are as defined in the specification and pharmaceutical composition comprising thereof, more specifically compound of the present invention is thiophenyl and pyrrolyl azepine compound; The compound is serotonin receptor (5-HT2c) ligand, useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT2c) is desired (e.g. addiction, anxiety, depression, obesity, and others).

The invention provides a juvenile network addiction early warning and reminding method and system based on physiological parameters, and belongs to the field of network addiction early warning, and the method comprises the steps: obtaining a facial image, a facial video stream and audio data of a user, and extracting the physiological feature data of the user from the facial image, the facial video stream and the audio data; sending the physiological feature data of the user to a background server; the background server is used for calculating physiological parameters based on the physiological feature data of the user, determining psychological parameters based on the questionnaire text data, the network application use data and the physiological parameters of the user, and calculating an addiction risk score based on the physiological parameters and the psychological parameters; in response to the received addiction risk score of the background server, if the addiction risk score is not less than a preset addiction risk threshold, determining a target early warning level based on the addiction risk score; and generating early warning information based on the target early warning level. According to the application, the addiction state of the juveniles can be accurately monitored and early warned.

The present invention provides a composition for use as anti-addiction in mitragynine addiction symptoms, characterized in that the composition comprises FPL 64176 as an active ingredient by reducing levels of calretinin and dopamine in a subject's brain.

The invention belongs to the field of network addiction detection, and provides a network space addiction behavior index system construction method and device, equipment and a medium, and the method comprises the steps: obtaining an index and an addiction level of a network space addiction behavior, and determining a visual angle; performing two-point anchor point selection processing on the visual angle to obtain an anchor point set; according to the anchor point set, a similarity graph, a diversity graph and a consistency graph of the anchor points are constructed, and the similarity graph, the diversity graph and the consistency graph are used for representing the incidence relation of the view angles; performing fusion calculation on the diversity graph and the consistency graph of the anchor points to obtain a weighted similarity matrix; carrying out eigendecomposition on the weighted similarity matrix to obtain low-dimensional embedded representation, and carrying out supervised training on the low-dimensional embedded representation through a loss function to obtain a network space addiction behavior index system; and network addiction detection is carried out through the network space addiction behavior index system. According to the invention, the accuracy of user network addiction level identification is improved.

This invention provides a class of multi-target heteropeptides based on N-4-piperidinyl-N-phenylpropionamide analogs and neuropeptide FF. These heteropeptides use the small-molecule N-4-piperidinyl-N-phenylpropionamide and the polypeptide-structured neuropeptide FF as chemical templates. A series of peptide-small-molecule hybrid peptides are obtained by chemically coupling the pharmacophores of the N-4-piperidinyl-N-phenylpropionamide analog and the neuropeptide FF. In vivo pharmacological activity identification in animals shows that these heteropeptides possess analgesic activity without opioid-like side effects such as addiction and respiratory depression. Furthermore, compounds 1-4 and compounds 7-9 do not exhibit analgesic tolerance and can be used for long-term analgesic treatment of chronic pain. Therefore, these heteropeptides based on N-4-piperidinyl-N-phenylpropionamide analogs and neuropeptide FF can be used to prepare analgesic drugs.

A method of modulating a brain activity of a mammal is achieved by subjecting the mammal to transcranial magnetic stimulation (TMS) with a TMS apparatus at random variable pulse intervals for a time sufficient to modulate said brain activity. The method can also be used by administering electric stimulation to the brain. Improvement in a physiological condition or a clinical condition is achieved. Conditions to be treated include but are not limited to PTSD, autism spectrum disorder addiction (SUD) and Alzheimer's disease.

The invention discloses an intelligent ring early warning system for multi-dimensional hand action monitoring, and relates to the technical field of intelligent rings, and the system comprises a data acquisition module, a gesture extraction module, a behavior judgment module, an early warning module and a personalized module. According to the invention, scene-based and personalized judgment is adopted, and addiction critical points in different situations are accurately adapted, the behavior judgment module calculates behavior diversity indexes based on the distribution of three types of hand operation units and dynamically judges the addiction risk in combination with scene information and a personalized attention baseline, and the personalized module dynamically judges the addiction risk through clustering analysis of historical behaviors of a user. Different use scenes are divided, and the exclusive judgment base line of each scene is continuously updated, so that the system not only can adapt to risk identification of easily addicted scenes, but also can dynamically adjust the judgment standard along with user behavior habit changes, it is ensured that critical points about to be addicted can be accurately perceived in various scenes, misjudgment or missed judgment caused by general standards is avoided, and the user experience is improved. And the early warning accuracy is improved.

Provided herein are compounds of Formula (I) or pharmaceutically acceptable salts thereof. Further disclosed are nanoparticles comprising one of the compounds and methods of using the same to treat drug addiction, drug dependence, drug excess, opioid use disorder, pain, chronic pain, fibromyalgia, arthritis, or obesity. (I)

The application belongs to the technical field of medicines, and relates to an N-H aporphine nitrogen-containing heterocyclic derivative, a preparation method and application thereof.The N-H aporphine nitrogen-containing heterocyclic derivative comprises a compound shown in a general formula M, isomers thereof and pharmaceutically acceptable salts or hydrates thereof.The application introduces a nitrogen-containing heterocyclic ring into an aporphine derivative, and the disclosed N-H aporphine nitrogen-containing heterocyclic derivative can be applied in the preparation of medicines for preventing and / or treating obesity, urinary incontinence, depression, anxiety, obsessive-compulsive disorder, epilepsy, schizophrenia, pain, diabetes and drug addiction.

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the brain. The focused ultrasound signal can have a mechanical index of between about 1.0 to about 8.0 and / or an acoustic pressure of between about 1.0 MPa to about 3.0 MPa. The medical condition can comprise addiction (including binge eating), anxiety disorders and anxiety associated disorders, tinnitus, neurodegenerative disorders, neuropsychiatric disorders, cognitive disorders, neurodevelopmental disorders, post-traumatic stress disorder, stroke recovery, and combinations thereof.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).

The present invention relates to a pharmaceutical composition for treating drug addiction comprising opioid receptor nanodiscs and to a method for preparing opioid receptor nanodiscs. Specifically, the opioid receptor nanodiscs, according to the present invention, inhibit the interaction between an opioid receptor and an opioid-based drug without exhibiting toxicity in the body, are delivered to the brain when administered into the body, and significantly restore the delay in a hot-plate response caused by opioid-based drug addiction, thereby being usefully applicable to treatment of opioid-based drug addiction.

Cannabinoid analogs may exhibit anti-inflammatory properties such as by inhibition of cannabinoid type 2 (CB2) receptors. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat various diseases and conditions in mammals, including pain, anxiety, a sleep disorder, addiction, epilepsy, depression, post-traumatic stress disorder or Alzheimer's disease. In some examples, the pharmaceutical compositions may be administered for treating a cognitive disorder or for improving cognition.

The invention is suitable for the technical field of artificial intelligence and the technical field of big data, and provides an anti-addiction early warning system and early warning method based on a causal discovery network, the anti-addiction early warning system comprises a central server and a plurality of client devices, and the central server is used for sending a global model to the plurality of client devices; the central server is used for receiving the local model update quantity uploaded by each client device, aggregating the local model update quantity of each client device by adopting an aggregation formula, generating an early warning model, and pushing the early warning model to a target client device in the plurality of client devices; and the target client device generates an attribution report of the current user through the causal discovery network in the early warning model, and generates an early warning message and an intervention suggestion of the current user in the aspect of network addiction based on the attribution report of the current user and the intelligent agent. According to the invention, the reliability of early warning messages and intervention suggestions can be improved.

The invention relates to the technical field of medicinal and edible substances and traditional Chinese pharmacology, and particularly discloses a medicinal and edible nicotine caffeine addiction inhibition formula. The traditional Chinese medicine is prepared from the following raw materials: paederia scandens, gardenia and old pericarpium citri reticulatae. The preparation method comprises the following steps: S1, respectively taking the paederia scandens, the fructus gardeniae and the old pericarpium citri reticulatae, and performing cleaning and drying treatment; s2, respectively crushing the paederia scandens, the cape jasmine and the old pericarpium citri reticulatae which are treated in the step S1, and sieving to obtain raw material coarse powder; s3, uniformly mixing the raw material coarse powder in proportion to obtain a mixed material; s4, extracting the mixed material to obtain an extracting solution; s5, concentrating the extracting solution to obtain clear paste; and S6, drying the clear paste to prepare the required dosage form. The addiction inhibition formula can be used for preparing medicines or functional foods for inhibiting nicotine and caffeine nervous addiction, and has the advantages of performing targeted intervention on nervous excitation pathways and realizing efficient, safe and multi-path addiction inhibition.

Polymeric particles and scaffolds containing anesthetic agents, their use for sustained local delivery of anesthetic agents, reduction of pain killer addiction and addiction risk, and methods of fabricating and administering polymeric particles containing anesthetic agents are described herein.

The invention relates to the technical field of medicines, and particularly discloses application of 9-anthraformic acid in preparation of a non-addictive peripheral analgesic medicine. It is proved for the first time that 9-anthracene formic acid has a remarkable analgesic effect and can effectively relieve inflammatory pain, the action target is a peripheral part, central side effects such as addiction and respiratory depression of traditional opioid analgesic are avoided, gastrointestinal injury, cardiovascular risk and curative effect capping effect of non-steroidal anti-inflammatory drugs are also overcome, and the 9-anthracene formic acid can be applied to preparation of anti-inflammatory drugs. Animal experiments prove that the analgesic effect of the compound is comparable with that of classical opioid drug morphine, and a brand new candidate drug and an application direction are provided for developing novel non-addiction analgesic drugs.

The present disclosure provides a compound of formula (I): JPEG2026506861000048.jpg37170, or a pharmaceutically acceptable salt and / or solvate thereof. The present disclosure also relates to the use of the compounds of formula (I) as pharmaceuticals, in particular for the prevention or treatment of addictions, obsessive-compulsive disorders and related behaviors, including obsessive-compulsive disorders and eating disorders, and neurodegenerative disorders such as Parkinson's disease or Alzheimer's disease.

The invention discloses a medicine for relieving pain. The medicine contains a compound which is used for acupoint administration and is used for targeted excitation of Piezo1 protein. The invention further discloses application of the Piezo agonist in preparation of the medicine for relieving pain. The invention relates to application of a Piezo agonist in relieving neuropathic pain after peripheral nerve injury, and provides a novel non-central analgesic treatment choice for neuropathic pain through a targeted peripheral mechanism. Micro-injection only needs to be carried out at the acupuncture point, systemic side effects of a traditional analgesic medicine are effectively avoided, the central safety is high, the addiction risk is avoided, compared with 20-30 minutes of needle retaining time generally needed by traditional acupuncture treatment of a single acupuncture point, the time consumed by acupuncture point injection is remarkably shortened, and the clinical efficiency requirement is better met.

The invention relates to the technical field of biological medicines, in particular to application of N-acetylneuraminic acid in preparation of a medicine for treating methamphetamine addiction. The key effect of N-acetylneuraminic acid (Neu5Ac) in methamphetamine addiction treatment is found for the first time, the CPP score of a methamphetamine addiction mouse can be obviously reduced, it is proved that the N-acetylneuraminic acid (Neu5Ac) has a good treatment effect on methamphetamine addiction, and Neu5Ac can be subjected to endogenous synthesis and has the advantages of being good in biocompatibility and small in toxic and side effect.

The invention discloses a method and a system for identifying network addiction based on Lauxia ink mark test and a storage medium, and the method comprises the following steps: presenting a Lauxia ink mark test graph card to a subject, and recording the response data of the subject to the graph card; based on the reaction data, through a preset coding rule, multiple Luxia ink mark test variables are extracted, and the variables at least comprise the interpersonal interest Hum Cnt, the personalized reaction PER, the pressure tolerance related variable D score, the shape use distortion ratio X-% and the human motion active and passive ratio Ma: Mp; substituting the extracted variable values of Hum Cont, PER, D, X-% and Ma: Mp into a predetermined logistic regression model, and calculating to obtain a probability value P that the tested object is identified as the network addiction; and based on the probability value P, outputting a network addiction risk assessment result. According to the invention, the deep insight of the Lauxia ink mark test is combined with the modern data analysis and computer-aided technology, and efficient, objective and accurate identification and early warning of the college student network addiction are realized.

Methods for the treatment of addiction and / or dependence are provided, methods to promote the cessation of various addictions, such as smoking and / or vaping, and methods to promote a reduction of various addictions, such as smoking and / or vaping, uses of cytisine as a treatment to quit addiction and dosage regimens for the above.

Methods of treating addictions and / or dependencies, methods of promoting the deactivation of various addictions, such as smoking and / or vaporizing e-cigarettes, and methods of promoting the reduction of various addictions, such as smoking and / or vaporizing e-cigarettes, the use of cytisine as an addiction deactivation treatment, and dosage regimens for the foregoing are provided.

Pharmaceutical formulations comprising buromantan or analogs of buromantan are disclosed, as well as methods of using the formulations for pharmaceutical therapy to reduce withdrawal syndrome and prevent relapse in the treatment of stimulant use disorders, to quit patients from drugs having a predisposition to abuse or addiction, or to promote regression learning in the treatment of mental disorders.

The invention relates to a head massage device for assisting in improving depression related physiological symptoms, and the head massage device comprises a helmet body module, the helmet body module comprises a helmet shell, one side of the helmet shell is provided with a vertical adjusting mechanism, and the other side of the helmet shell is provided with a horizontal adjusting mechanism. The vertical adjusting mechanism is internally provided with a vertical adjusting knob, a vertical adjusting belt and a magnetic conductive metal sheet which are linked with the vertical adjusting knob, a main coating air bag and a circumferential adjusting mechanism. The device is reasonable in structure, realizes nerve regulation through physical massage, has no drug metabolism burden, no addiction risk and no systematic adverse reaction, is particularly suitable for patients with mild and moderate depression, patients with drug intolerance, teenagers and old people, can be used as an effective supplement or alternative scheme of drug treatment, and has wide application prospects. Through the design of neck support self-adaptive adjustment, path separation and face avoiding and the like, it is ensured that a patient can comfortably use the pillow in a natural supine or side-lying sleeping posture, and the situation that neck ache is caused by equipment compression, and use of the depression patient is very easily interrupted due to discomfort is avoided.

This disclosure relates to heterocyclic compounds of Formula (I) as well as the preparation and use thereof. As contemplated herein, heterocyclic compounds of Formula (I) can be any one of a carbohydrate conjugate and an amino acid conjugate. The heterocyclic compounds of Formula (I) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate, and cocaine addiction, alcoholism, post-traumatic stress disorder (PTSD), and pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.